Join the club for FREE to access the whole archive and other member benefits.

'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases


Key points from article :

Underdog Pharmaceuticals has been awarded an Innovation Passport under the UK’s Innovative Licensing and Access Pathway (ILAP).

It is on a mission – not to treat age-related diseases, but to tackle the causes using simple and direct interventions.

By targeting oxidised cholesterol, it aims for the first true disease-modifying treatment for atherosclerosis, heart attack & stroke.

Products are based on novel derivatives of a well-known, safe compound.

Custom-engineered cyclodextrins tackle cholesterol derivatives such as 7-ketocholesterol.

UDP-003 is designed to target and remove toxic oxidised cholesterol, a key driver of arterial plaque accumulation.

Underdog is one of the first companies, and UDP-003 one of the very few pre-clinical therapies, to receive an ILAP designation.

“There is an enormous public need for drugs which can significantly reverse atherosclerosis, rather than manage or delay its onset,” - Matthew O’Connor, Underdog CEO of Scientific Affairs.

Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from blood

Mentioned in this article:

Click on resource name for more details.

Cyclarity Therapeutics

Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.

Matthew O’Connor

Co-Chief Executive Officer and Co-founder of Cyclarity Therapeutics (former Underdog Pharmaceuticals)